Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

52.53 +1.42 (+2.78%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why ↗

February 28, 2025

Via The Motley Fool

3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%. ↗

February 28, 2025

Via The Motley Fool

2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street ↗

February 24, 2025

Via The Motley Fool

Market Whales and Their Recent Bets on CRSP Options ↗

February 20, 2025

Via Benzinga

This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

February 18, 2025

Via Benzinga

WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗

February 16, 2025

Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)

Via Benzinga

1 big new Green Flag for CRISPR Therapeutics' Stock ↗

December 20, 2024

Via The Motley Fool

This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

February 14, 2025

Via Benzinga

This Informatica Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗

February 14, 2025

Via Benzinga

This Roku Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗

February 14, 2025

Via Benzinga

The Ultimate Healthcare Stock to Buy With $500 Right Now ↗

February 14, 2025

Via The Motley Fool

Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday ↗

February 12, 2025

Via The Motley Fool

Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday ↗

February 12, 2025

Via Benzinga

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. ↗

February 11, 2025

The company is entering a year of commercial launches. Those aren't guaranteed to put up cystic fibrosis-like numbers.

Via Investor's Business Daily

Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move ↗

February 10, 2025

Via The Motley Fool

Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug? ↗

February 02, 2025

Via The Motley Fool

Cathie Wood's Ark Invest Bets On Biotech With CRISPR Therapeutics Investment, Exits Roblox ↗

January 31, 2025

Cathie Wood-led Ark Invest made significant trades involving CRSP, TXG, RBLX, ACHR, NU, ADYEY, ACCD, and AVAV.

Via Benzinga

MaxCyte: Building the Future of Cell and Gene Therapy Innovation

January 23, 2025

MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.

Via MarketBeat

My Top 5 Stocks to Buy in Early 2025 ↗

January 23, 2025

Via The Motley Fool

Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases ↗

January 22, 2025

An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

Via Benzinga

3 Unstoppable Stocks to Buy in 2025 ↗

January 18, 2025

Via The Motley Fool

Cathie Wood's Ark Invest Is Betting Big On This AI Darling And No It's Not Nvidia ↗

January 18, 2025

Ark Invest made significant trades involving Tempus AI, CRISPR Therapeutics, UiPath, Roblox, Reddit, Accolade, and Ibotta. ARKG and ARKK funds bought shares, while ARKW and ARKF funds sold shares.

Via Benzinga

Topics Artificial Intelligence

2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows ↗

January 16, 2025

Via The Motley Fool

Vertex's Pain Drug: Big Pharma's Next Major Success?

January 16, 2025

Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market.

Via MarketBeat

My 10 Top Stocks to Buy to Start the New Year Off Right ↗

January 16, 2025

Via The Motley Fool

Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts ↗

January 14, 2025

Via The Motley Fool

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

3 Mid-Cap Stocks That Could Take Off in 2025 ↗

January 09, 2025

Via The Motley Fool

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

January 07, 2025

Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.

Via MarketBeat

This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy? ↗

December 22, 2024

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.